AstraZeneca, a global biopharma-ceutical company of Swedish-British origin, has partnered with MGH Healthcare Ltd to provide convenient and reliable access to its medicines in Bangladesh.
Together, they will increase awareness amongst physicians and patients about the science behind innovative treatments and will increase access to innovative treatments to make a difference for patients in Bangladesh, according to a statement.
MGH Healthcare will work as a distributor of AstraZeneca in Bangladesh.
The partnership was inaugurated by Zahid Maleque, health and family welfare minister, and Md Mustafizur Rahman, director general of the Directorate General of Drug Administration, at an event hosted by Business Sweden, the Swedish Trade and Invest Council in Dhaka, yesterday.
Swedish Ambassador Charlotta Schlyter and British High Commissioner Robert Chatterton Dickson were present.
“Through this partnership, AstraZeneca and MGH Healthcare Ltd aim to achieve our shared ambition to 'make our science accessible' as it will help us deliver innovative treatments to all patients who need it,” said Nitin Kapoor, president of AstraZeneca for Asean.
“AstraZeneca is committed to improving patient outcomes through scientific discovery and collaborations.”
AstraZeneca is a leader in the treatment of non-communicable diseases such as cancer and cardiovascular-metabolic-renal diseases, which are prevalent in Bangladesh.
Anis Ahmed, founder and Group CEO of MGH, said MGH was honoured to partner with AstraZeneca in Bangladesh.
“Through our valued partnership with AstraZeneca, we aim to serve and provide access to right medicines and offer best care to our Bangladesh patients.”
MGH Healthcare is renowned for wide distribution network services which integrate and manage the entire global value chain between suppliers, manufacturers, brand owners and customers like AstraZeneca, Omron, and Sanofi.